I have never pinned anything on X, but I am going to keep this thread calling out $CGEM as being undervalued pinned for a while, because I am feeling pretty confident about it. I want to call my shot on this one. The thread isn't short, but I hope it does a good job of documenting the general basis for what I think is a significant mispricing of Cullinan. In the $15s right now, the market cap is under a billion, and the EV is <$200M with their surprisingly strong balance sheet. Maybe there is some value in their oncology assets (they did get some good $ for half of zipalertinib ownership), but personally I am writing those off completely and focusing on CLN-978, their CD3xCD19 T-Cell Engager for I&I.

Thanks! You know, I actually give management significant credit for how they handled the IL-2 oncology situation. Not their fault there was hype around it - multiple pharmas blew billions on this idea, even for assets that came much later than NKTR. Management was able to secure an absolute boatload of cash at that time while still preserving upside in the event that the MOA worked out. Ultimately obviously it didn’t, but without that BMY deal this company would almost certainly not be around today to have this shot on goal for AD!

@LiteratureBios Ok but if we are out somewhere that’s gonna be more than $1,000 CAD and I won’t get any rev share?

@LiteratureBios Ok you nailed it so I’m obligated to hold up this seed offer. Obviously these figures were all CAD though hope this was obvious.

@JoseRestonVA @JusticeforB_MD Let me know. I’m pretty passionate on this situation and think it’s probably my favorite biotech setup of all time. 🫡

@Biotenic @lifeisblank21 AND ALSO WHAT TIME YOU GET LET OUT OF SCHOOL YOUNG MAN

@Biotenic @lifeisblank21

@lifeisblank21 @Biotenic There is no difference (at all!) between shorting a biotech stock and choking people lying in hospital beds.

@RockRat2 Server is smoking and monitor is flashing a red screen with bold text “cry”. Not sure tbh. Citadel won’t answer my calls now either.

@BertrandBio $GILD doing well, looks like they can afford to buy something. $BIIB doing badly, looks like they have got to buy something.

@Sanctuary_Bio La chancla vive

@drug_smolecules Inflation commentary or bird flu commentary?

@LiteratureBios Sounds good let's see what happens. LMK what you think of the terms (non-negotiable) and who you wanna prime with.

Lmao you literally can’t even read/understand your own tweet, bagholder 😂 😂 😂 “Peptide chemistry is pretty simple. It's pretty low tech. It's scalability that is the challenge”. SCALABILITY IS THE CHALLENGE. Literally right from Lian, as you just posted but were unable to comprehend. You literally are precisely making my point that directly refutes yours 😂 Your idiocy never ceases to amaze me. It’s so bad that it’s almost as far beyond my comprehension that someone could be so dumb as basic reading skills are to you. Shut up, give up, and leave me alone unless you want to keep getting repeatedly humiliated. Btw, Lian is not a peptide chemist like you just said (then deleted). He worked in small molecule discovery at Amgen.

@jfais20 @jayabacus

@cloud_walker200 @cigs1234 ~50x the api of TZP. ~300x the API of sema. It’s a big deal, and the reason that Brian has repeatedly said the oral is not the lead value driver for the company.